Cardiome Pharma

Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development, and commercialization of new therapies to improve the health of patients with heart disease worldwide. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), which is approved in Europe and other regions for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.